NewsBenzingaCanaccord Genuity维持对Candel Therapeutics的买入评级,将目标价下调至13美元 Canaccord Genuity维持对Candel Therapeutics的买入评级,将目标价下调至13美元 Benzinga 2026.11.13 13:38 (GMT+0) Open on Benzinga Other news Nvidia Shares Rise After Earnings Beat in First Report Since Jensen Huang's Exit NVIDIA Chairman Harvey Jones: Board Has No Intention of Restoring Jensen Huang as CEO Slower Retail Sales Drag on Market SEC reportedly investigating Nvidia amid Huang exit A $3 Billion Reason Why Disney Stock Is in Focus Today Google joins the tech outage trend by announcing it’s not having one